Overview

Etoricoxib in Ear Nose Throat Surgery

Status:
Unknown status
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The aim of this study is to test the analgesic efficacy of etoricoxib (90 mg or 120 mg qd. perioperatively) for post-operative pain relief. The primary endpoint is as follows: - does preoperative etoricoxib reduce the post-operative opioid utilization in patients undergoing elective tonsillectomy under general anaesthesia (i.e. the post-operative opioid-sparing effect of etoricoxib in humans). The secondary endpoints are as follows: - does the etoricoxib medication have an impact on PONV or activities of daily - does the etoricoxib medication influence the blood loss during surgery or the incidence of postoperative bleeding - does the etoricoxib medication influence the operation time. In addition, adverse effects of etoricoxib will be documented.
Phase:
Phase 3
Details
Lead Sponsor:
University of Regensburg
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Etoricoxib